Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes

Environmental Health Perspectives

Volumn 114, Issue 8, 2006, Pages 1233-1236

  Li, Wan Fen ^a   Pan, Mei Hung ^b   Chung, Meng Chu ^a   Ho, Chi Kung ^c   Chuang, Hung Yi ^b,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Atherosclerosis; Lead; Metal; Paraoxonase; Polymorphism

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE 1; CYTOSINE; GLUTAMINE; LEAD; LEUCINE; METHIONINE; THYMINE;

ADULT; ALLELE; ARTICLE; ATHEROSCLEROSIS; BATTERY INDUSTRY; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOTE; HUMAN; INDUSTRIAL WORKER; ISCHEMIC HEART DISEASE; LEAD BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RECYCLING; RISK FACTOR; STATISTICAL SIGNIFICANCE;

ADULT; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CHOLESTEROL; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; LEAD; LIPIDS; LIPOPROTEINS; MALE; METALLURGY; OCCUPATIONAL EXPOSURE; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; TAIWAN;

ANIMALIA;

EID: 33746877938     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1021/ol060125u     Document Type: Article

References (33)

1. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. 1998. Paraoxonase active site required for protection against LD L oxidation involves its free suffhydryl group and is different from that required for its arylesterase/pareoxonase activities: selective action of human paraoxonese allozymes Q and R. Arterioscler Thromb Vasc Biol 18(10):1617-1624.
2. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE. 2001. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11(1):77-84.
3. Bub A, Barth S, Watzl B, Briviba K, Herbert BM, Luhrmann PM, et al. 2002. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in R-allele-carrier but not in QQ homozygous elderly subjects on atomato-rich diet. Eur J Nutr 41(6):237-243.
4. CDC. 2005. Preventing Lead Poisoning in Young Children. Atlanta, GA:-Centers for Disease Control and Prevention.
5. Cole TB, Li WF, Richter RJ, Furlong CE, Costa LG. 2002. Inhibition of poraoxonase JPON1) by heavy metals [Abstract]. Toxicol Sci 66(1-S):312.
6. Debord J, Ballinger JC, Merle L, Dantoino T. 2003. Inhibition of human serum arylesterase by metal chloridles. J Inorg Biochem 94(1-2):1-4.
7. el-Gazzar RM, el-Hefny SA, Noweir KH, Shamy MY. 1989. Study of the lipoprotein pattern among workers exposed to lead. J Egypt Public Health Assoc 64(5-6):571-585.
8. Furlong CE, Richter RJ, Seidel SL, Costa LG, Motulsky AG. 1989. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonese/ arylesterase. Anal Biochem 180(2):242-247.
9. Furlong CE, Richter RJ, Seidel SL, Motulsky AG. 1988. Role of genetic polymorphism of human plasma paraoxonase/arylesterese in hydrolysis of the insecticide metabolites chlorpyrifos oxen and paraoxon. Am J Hum Genet 43(3):230-238.
10. Gonzalvo MC, Gil F, Hernandez AF, Villanueva E, Pla A. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 105(3):169-179.
11. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. 2004. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11(5):412-419.
12. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3(1):73-76.
13. Institute of Occupational Safety and Health. 2002. Handbook for Prevention of Lead Poisoning. Taipei, Taiwan:Institute of Occupational Safety and Health.
14. Ito Y, Niiya Y, Kurita H, Shime S, Sarai S. 1985. Serum lipid peroxide level and blood superoxide dismutase activity in workers with occupational exposure to lead. Int Arch Occup Environ Health 56(2):119-127.
15. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schallenberg GD, et al. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20(11):2441-2447.
16. Kristal-Boneh E, Coller D, Froom P, Harari G, Ribak J. 1999. The association between occupational lead exposure and serum cholesterol and lipoprotein levels. Am J Public Health 89(7):1083-1087.
17. Lustberg M, Silbergeld E. 2002. Blood lead levels and mortality. Arch Intern Med 162(21):2443-2449.
18. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21(9):1451-1457.
19. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. 2003. Low paraoxonese activity predicts coronary events in the Caerphilly prospective study. Circulation 107(22):2775-2779.
20. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. 1998. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Left 423(1):57-60.
21. Navas-Acien A, Selvin E, Sharrett AR, Calderon-Arande E, Silbergeld E, Guallar E. 2004. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 109(25):3195-3201.
22. Nawrot TS, Thijs L, Den Hond EM, Roels HA, Staessen JA. 2002. An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens 16(2):123-131.
23. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM. 2002. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 290(3):921-927.
24. OSHA (Occupational Safety and Health Administration). 2003. Occupational Safety and Health Standards: Toxic and Hazardous Substances: Load. 29CFRI910.1025.
25. Richter RJ, Furlong CE. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9(6):745-753.
26. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. 2003. Paraoxonose (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 34(6):774-784.
27. Senti M, Aubo C, Elosua R, Sala J, Tomas M, Marrugat J. 2000. Effect of physical activity on lipid levels in a population-based sample of men with and without the Arg192 variant of the human paraoxonase gene. Genet Epidemiol 18(3):275-286.
28. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. 1998. Mice lacking serum paràoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394(6690):284-287.
29. Skoczynska A, Smolik R, Jelen M. 1993. Lipid abnormalities in rats given small doses of lead. Arch Toxicol 67(3):200-204.
30. Tomas M, Senti M, Elosua R, Vila J, Sala J, Masia R, et al. 2001. Interaction between the Gln-Arg 192 variants of the paraoxonase gone and oleic acid intake as a determinant of high-donsity lipoprotein cholesterol and paraoxonase activity. Eur J Pharmacol 432(2-3):121-128.
31. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106(4):484-490.
32. Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, et al. 2003. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 23(2):328-334.
33. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. 2004. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363(9410):689-695.